These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34784508)

  • 41. Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.
    Sun P; Crum-Cianflone NF; Defang G; Williams M; Ganesan A; Agan BK; Lalani T; Whitman T; Brandt C; Burgess TH
    Vaccine; 2017 Oct; 35(45):6103-6111. PubMed ID: 28987439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.
    Roy-Ghanta S; Van der Most R; Li P; Vaughn DW
    J Infect Dis; 2014 Nov; 210(9):1419-30. PubMed ID: 24864125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.
    Liebowitz D; Lindbloom JD; Brandl JR; Garg SJ; Tucker SN
    Lancet Infect Dis; 2015 Sep; 15(9):1041-1048. PubMed ID: 26333337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination.
    He XS; Holmes TH; Sanyal M; Albrecht RA; García-Sastre A; Dekker CL; Davis MM; Greenberg HB
    J Infect Dis; 2015 Apr; 211(7):1051-9. PubMed ID: 25336731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an Alternative Modified Live Influenza B Virus Vaccine.
    Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
    Hessel A; Schwendinger M; Fritz D; Coulibaly S; Holzer GW; Sabarth N; Kistner O; Wodal W; Kerschbaum A; Savidis-Dacho H; Crowe BA; Kreil TR; Barrett PN; Falkner FG
    PLoS One; 2010 Aug; 5(8):e12217. PubMed ID: 20808939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial.
    L'huillier AG; Ferreira VH; Hirzel C; Natori Y; Slomovic J; Ku T; Hoschler K; Ierullo M; Selzner N; Schiff J; Singer LG; Humar A; Kumar D
    J Infect Dis; 2020 Jan; 221(1):53-62. PubMed ID: 31550354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coadministration of Recombinant Adenovirus Expressing GM-CSF with Inactivated H5N1 Avian Influenza Vaccine Increased the Immune Responses and Protective Efficacy Against a Wild Bird Source of H5N1 Challenge.
    Wang X; Wang X; Jia Y; Wang C; Tang Q; Han Q; Xiao S; Yang Z
    J Interferon Cytokine Res; 2017 Oct; 37(10):467-473. PubMed ID: 29028432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.
    Wang X; Fu W; Yuan S; Yang X; Song Y; Liu L; Chi Y; Cheng T; Xing M; Zhang Y; Zhang C; Yang Y; Zhu C; Zhang X; Xiong S; Xu J; Zhou D
    Sci Rep; 2017 May; 7(1):1854. PubMed ID: 28500340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
    Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
    Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
    Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
    PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.
    Carter DM; Darby CA; Johnson SK; Carlock MA; Kirchenbaum GA; Allen JD; Vogel TU; Delagrave S; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
    Ni Y; Guo J; Turner D; Tizard I
    Front Immunol; 2018; 9():1815. PubMed ID: 30140267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.
    van Doorn E; Liu H; Ben-Yedidia T; Hassin S; Visontai I; Norley S; Frijlink HW; Hak E
    Medicine (Baltimore); 2017 Mar; 96(11):e6339. PubMed ID: 28296763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.
    Combadière B; Vogt A; Mahé B; Costagliola D; Hadam S; Bonduelle O; Sterry W; Staszewski S; Schaefer H; van der Werf S; Katlama C; Autran B; Blume-Peytavi U
    PLoS One; 2010 May; 5(5):e10818. PubMed ID: 20520820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs.
    Thomas M; Wang Z; Sreenivasan CC; Hause BM; Gourapura J Renukaradhya ; Li F; Francis DH; Kaushik RS; Khatri M
    Vaccine; 2015 Jan; 33(4):542-8. PubMed ID: 25437101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.